Paul Carter
Director/Board Member bij HUTCHMED (CHINA) LIMITED
Vermogen: 701 786 $ op 31-03-2024
Profiel
Paul Rutherford Carter is currently the Non-Executive Chairman at Evox Therapeutics Ltd., the Senior Independent Non-Executive Director at HUTCHMED (China) Ltd., the Director at Concentric Analgesics, Inc., the Independent Non-Executive Director at Immatics NV, a Director at VectivBio AG, and an Independent Director at Awakn Life Sciences Corp.
Previously, he served as an Independent Director at Mallinckrodt Plc, Lundbeck Seattle BioPharmaceuticals, Inc., and VectivBio Holding AG.
He also held the position of Executive Vice President-Commercial Operations at Gilead Sciences, Inc. and Regional Vice President-China & Hong Kong at GSK Plc.
Mr. Carter completed his undergraduate degree at the University of West London in 1983.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
IMMATICS N.V.
0.05% | 31-01-2024 | 55 313 ( 0.05% ) | 581 340 $ | 31-03-2024 |
HUTCHMED (CHINA) LIMITED
0.00% | 20-04-2024 | 35 240 ( 0.00% ) | 120 447 $ | 31-03-2024 |
AWAKN LIFE SCIENCES CORP
-.--% | 26-01-2024 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Paul Carter
Bedrijven | Functie | Begin |
---|---|---|
HUTCHMED (CHINA) LIMITED | Director/Board Member | 01-02-2017 |
IMMATICS N.V. | Director/Board Member | 01-07-2020 |
AWAKN LIFE SCIENCES CORP. | Director/Board Member | 14-12-2021 |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | Chairman | 14-05-2020 |
Concentric Analgesics, Inc.
Concentric Analgesics, Inc. Packaged SoftwareTechnology Services Concentric Analgesics, Inc. develops novel, non-opioid therapeutics for the management of acute postsurgical and chronic osteoarthritis pain. The company was founded by John F. Donovan, Frank J. Bellizzi and Craig O. Husfeld in 2014 and is headquartered in San Francisco, CA. | Director/Board Member | 26-01-2022 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Director/Board Member | - |
Eerdere bekende functies van Paul Carter
Bedrijven | Functie | Einde |
---|---|---|
VECTIVBIO HOLDING AG | Director/Board Member | 26-06-2023 |
MALLINCKRODT PLC | Director/Board Member | 16-06-2022 |
ALDER BIOPHARMACEUTICALS, INC. | Director/Board Member | 01-11-2019 |
░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Opleiding van Paul Carter
University of West London | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 5 |
---|---|
GILEAD SCIENCES, INC. | Health Technology |
HUTCHMED (CHINA) LIMITED | Health Technology |
MALLINCKRODT PLC | Health Technology |
GSK PLC | Health Technology |
IMMATICS N.V. | Health Technology |
Bedrijven in privébezit | 6 |
---|---|
Lundbeck Seattle BioPharmaceuticals, Inc.
Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
Concentric Analgesics, Inc.
Concentric Analgesics, Inc. Packaged SoftwareTechnology Services Concentric Analgesics, Inc. develops novel, non-opioid therapeutics for the management of acute postsurgical and chronic osteoarthritis pain. The company was founded by John F. Donovan, Frank J. Bellizzi and Craig O. Husfeld in 2014 and is headquartered in San Francisco, CA. | Technology Services |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | Health Technology |
VectivBio Holding AG
VectivBio Holding AG Pharmaceuticals: MajorHealth Technology VectivBio Holding AG is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of treatments for severe rare conditions with significant unmet medical need. It operates through Switzerland, Canada, and the United States geographical segment. The company was founded by Luca Santarelli on May 22, 2019 and is headquartered in Basel, Switzerland. | Health Technology |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Health Technology |
Awakn Life Sciences Corp. |